Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | The importance of genomic testing in the diagnosis of CLL

Michel van Gelder • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia

Michel van Gelder, MD, PhD, Maastricht University, Maastricht, Netherlands, discusses the importance of genomic testing as a diagnostic tool for chronic lymphocytic leukemia (CLL), including identifying IGHV mutations and TP53 abnormalities, as this provides key information about life expectancy and which therapeutic route to take. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michel van Gelder

2:18
How patients are involved in treatment decisions following a genomic test
Michel van Gelder • 7 Oct 2022
3:51
The role of frontline chemoimmunotherapy in the era of novel agents in CLL
Michel van Gelder • 7 Oct 2022

Related Videos

6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
1:56
Approaching treatment selection and sequencing with the recent influx of BTK inhibitors in CLL
Dima El-Sharkawi • 28 Apr 2024
1:17
Using an AI model to quantify under-utilization of alloSCT for AML in the UK
Thomas Coats • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals